Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies and will participate in two investor conferences in September 2025 [1][5]. Company Overview - BBOT is advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors [4]. Conference Participation Details - BBOT will participate in the Cantor Global Healthcare Conference with a fireside chat scheduled for Thursday, September 4 at 8:35 a.m. ET, along with hosting investor meetings in New York [5]. - The company will also participate in the Morgan Stanley Global Healthcare Conference with a fireside chat on Monday, September 8 at 7:45 a.m. ET, and will host additional investor meetings in New York [5].